SavedAdd your journal

Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2011 / Cilt: 64 - Sayı: 3

Protective vaccine researches in Shigella İnfections

Shigella infeksiyonlarında koruyucu așı çalıșmaları

Birsel ERDEM
Begüm SARAN
Pages
105–110
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, vaccine developement strategies for obtaining protective and safe vaccines from past to now are investigated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Shigella, a member of enterobacteriaceae, is endemic over the world and causes infections with high mortality rates especially in developing countries.
📊
Key Findings & Data:Disease is more common among children under 5 years old and is an important cause of children death in world.
💡
Conclusion & Impact:In this review, vaccine developement strategies for obtaining protective and safe vaccines from past to now are investigated.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Shigella, a member of enterobacteriaceae, is endemic over the world and causes infections with high mortality rates especially in developing countries. Disease is more common among children under 5 years old and is an important cause of children death in world. World health organisation (WHO) consider the researches of a protective vaccine developement for shigellosis as a priority. Protective vaccines for Shigella infections are focused on conjugate vaccines based on bacterial O polysaccharide linked to a carrier protein administered by parenteral, oral or intranasal; live attenued vaccines conferring protection without causing disease; live oral vaccines obtained by genetic process following the discover of genes involved in pathogenesis; hybrid live vector Shigella vaccines; wide spectrum vaccines and invazincomplex vaccines. Last years, since virulance factors and pathogenesis of Shigella are discovered, promising vaccines for future are developed. In this review, vaccine developement strategies for obtaining protective and safe vaccines from past to now are investigated.

Özet

Enterobacteriaceae ailesinin bir üyesi olan Shigella cinsi tüm dünyada endemik olarak görülmekte, özellikle gelișmekte olan ülkelerde yüksek mortalite ile seyreden infeksiyonlara neden olmaktadır. Hastalık çoğunlukla 5 yașın altındaki çocuklarda görülmekte ve dünyada çocuk ölümü nedenlerinin arasında önemli bir yer tutmaktadır. Dünya Sağlık Örgütü (WHO) șigelloza karșı koruyucu așı geliștirme çalıșmalarını öncelikleri arasına almıștır. Shigella infeksiyonları için koruyucu așılar, bakteri O polisakkariti tașıyıcı bir protein ile bağlanarak parenteral, oral veya intranazal uygulanan konjuge așılar; hastalık olușturmadan koruyucu etki sağlamayı hedefleyen canlı attenue așılar; patogenezde rol oynayan genlerin aydınlatılması ile genetik yoldan elde edilecek canlı oral așılar; hibrit canlı vektör Shigella așıları; geniș spektrumlu așılar ve invazin kompleks așısı üzerinde yoğunlașmıștır. Son yıllarda Shigella virülans faktörlerinin ve patogenezinin iyice aydınlatılması ile gelecekte umut vaad eden așılar elde edilmiștir. Bu derlemede, koruyucu ve güvenilir așı elde etmek için geçmișten günümüze yapılan așı geliștirme stratejileri incelenmiștir.

🔖

Cite This Article

ERDEM, B., SARAN, B. (2022). Protective vaccine researches in Shigella İnfections. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 64 - Sayı: 3, 105–110. https://ajindex.com/articles/443793

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Dupont, HL. Shigella Species (Bacillary Dysentery). In: Mandell GL, Bennett JE, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone Elsevier.; 2010. p. 2905-2919. Aysev AD. Shigella Türleri. In: Topçu AW, Söyletir G, Doğanay M, editors. İnfeksiyon Hastalıkları ve Mikrobiyolojisi, Etkenlere Göre İnfeksiyonlar. İstanbul: Nobel Tıp Kitapevleri.; 2008. p. 2164- 2168. Butler T, Scheld WM. Shigellosis. In: Goldman L, Ausiello D, editors. Cecil Textbook of Medicine. Philadelphia: Saunders.; 2004. p. 1852-1854. Erdem B. Enterobacteriaceae. In: Mutlu G, İzmir T, Cengiz AT, Ustaçelebi Ş, Tümbay E, Mete Ö editors. Temel ve Klinik Mikrobiyoloji. Ankara: Güneş Kitabevi.; 1999. p. 471-515.
  2. Black RE, Lanata CF. Diarrheal Diseases. In: Nelson KE, Williams CFM, editors. Infectious Disease Epidemiology: Theory and Practice. Massachusetts: Jones and Bartlett Publishers.; 2007. p. 759-786.
  3. Levine MM, Kotloff KL, Barry EM, et al. Clinical Trials of Shigella Vaccines: Two Steps forward and One Step Back On a Long, Hard Road. Nat Rev Microbiol 2007;5(7): 540–553. Ferreccio C, Prado V, Ojeda A, et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol 1991;134: 614–627. Tacket CO, Binion SB, Bostwick E, et al. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am. J. Trop. Med. Hyg 1992;47: 276-283.
  4. Kaminski RW, Oaks EV. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev Vaccines 2009;8(12): 1693- 1704. Cohen D, Ashkenazi S, Green M, et al. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun 1996;64: 4074–4077. Cohen D, Ashkenazi S, Green MS, et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997;349(9046): 155-159.
  5. Ashkenazi S, Passwell JH, Harlev E, et al. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J Infect Dis 1999;179(6): 1565-1568.
  6. Passwell JH, Ashkenazi S, Harlev E, et al. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2arEPAsucc conjugate vaccines in 1–4- yearold children. Pediatr Infect Dis J 2003;22(8): 701–706. Chowers, Y., Kirschner, J., Keller, et al. O-Specific polysaccharide conjuga